Quantcast
Last updated on April 18, 2014 at 9:25 EDT

Latest ARMAGEN Stories

2013-09-04 08:32:35

CALABASAS, Calif., Sept. 4, 2013 /PRNewswire/ -- ARMAGEN, a leader in the field of transporting therapeutics across the blood brain barrier (BBB) today announced the issuance of two additional patents by the U.S. Patent and Trademark Office (USPTO). Based on the work of Dr. William Pardridge, these new patents reinforce ARMAGEN's already dominant intellectual property position for the Company's novel platform for delivery of therapeutics across the BBB into the central nervous system...

2013-07-18 12:28:16

SANTA MONICA, Calif., July 18, 2013 /PRNewswire/ -- ARMAGEN announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead product AGT-182 for the treatment of mucopolysaccharidosis type II (also known as Hunter syndrome or MPS II.) Hunter syndrome is a rare, genetic lysosomal storage disease caused by a deficient or absent enzyme, iduronate-2-sulfatase. It is a life-threatening disease affecting children as young as 2 years of age....